avelumab + utomilumab + PF-04518600

Avelumab + utomilumab + PF-04518600 is an investigational **triple combination immunotherapy** composed of avelumab (a fully human anti-PD-L1 IgG1 monoclonal antibody), utomilumab (a fully human IgG2 monoclonal antibody agonist of 4-1BB/CD137), and PF-04518600 (a humanized agonist IgG2 monoclonal antibody targeting OX40). - **Avelumab** blocks the interaction between PD-L1 and its receptors, thereby restoring T-cell mediated antitumor immunity. - **Utomilumab** activates 4-1BB, a costimulatory receptor on T cells and NK cells, enhancing immune cell activation and antitumor activity. - **PF-04518600 (anti-OX40)** stimulates OX40, a costimulatory molecule expressed on activated T-cells, promoting T-cell proliferation and survival. The combination is designed to enhance antitumor immune responses by targeting multiple immune checkpoints and co-stimulatory pathways. It is under early-phase clinical study for patients with advanced solid tumors and various cancers, including gastrointestinal and lymphoid malignancies[2][3][6].

Other names

anti-PD-L1 (avelumab)anti-4-1BB (utomilumab)anti-OX40 (PF-04518600)